Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SinoMab Bioscience Ltd. ( (HK:3681) ) has issued an update.
SinoMab BioScience Limited has completed the subscription of 24,965,400 new shares under a general mandate with Subscribers H and O. This issuance, which represents approximately 1.80% of the company’s enlarged share capital, is expected to generate net proceeds of about HK$50.68 million, impacting the company’s shareholding structure and potentially enhancing its financial position.
The most recent analyst rating on (HK:3681) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a Hong Kong-based company operating in the biopharmaceutical industry. It focuses on the development and commercialization of therapeutics for the treatment of immunological diseases.
Average Trading Volume: 22,579,208
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.12B
See more data about 3681 stock on TipRanks’ Stock Analysis page.